Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Cardiology · Coronary artery stenosis

Medications and Lifestyle: The Foundation of Care

At a Glance

For selected people with stable coronary stenosis, guideline-directed medical therapy—heart medicines, smoking cessation, cardiac rehabilitation, and control of blood pressure and diabetes—can reduce future risks; stents mainly help when symptoms persist or disease is high risk.

For many years, the standard response to finding a narrowed heart artery was to “fix” it with a stent or surgery. However, modern research has transformed our understanding of coronary stenosis. We now know that for most people with stable symptoms, the foundation of a long and healthy life isn’t a procedure—it is Guideline-Directed Medical Therapy (GDMT) [1][2].

What is GDMT?

GDMT is a comprehensive, evidence-based approach to treating heart disease using the most effective combinations of medications and lifestyle changes. Rather than just opening one “clogged pipe,” GDMT treats your entire circulatory system, stabilizing plaques throughout your heart to prevent future events [3][2].
(Note: GDMT is individualized. Do not start or stop medications, especially antiplatelets, without consulting your care team.)

The Core Medications

Standard medical therapy for coronary stenosis usually involves several classes of drugs, each with a specific job:

  • Lipid-Lowering Therapy: Statins are the cornerstone of treatment. They don’t just lower cholesterol; they “stabilize” plaques, making them less likely to rupture [3]. For many patients, the goal is an LDL-C (bad cholesterol) of 70 mg/dL or lower, though some high-risk guidelines suggest below 55 mg/dL [4]. If statins alone aren’t enough, doctors may add ezetimibe or PCSK9 inhibitors (injectable medications) to reach these individualized targets [4][5].
  • Antiplatelet Therapy: These medications, such as low-dose aspirin or clopidogrel, prevent blood cells (platelets) from sticking together. This reduces the risk of a blood clot forming at the site of a plaque [6][7].
    (Antiplatelet choice and duration are highly individualized based on bleeding risk and whether you have had a stent or heart attack. Never stop taking your prescribed antiplatelet medication after a stent without your cardiologist’s explicit instruction, as this can cause a life-threatening clot.)
  • Anti-Anginal Medications: Drugs like beta-blockers, calcium-channel blockers, and nitroglycerin help the heart work more efficiently and reduce chest pain [8][9]. A newer option called ranolazine can help relieve pain without affecting your heart rate or blood pressure [10].
  • Anti-Inflammatory Therapy: Because heart disease is an inflammatory condition, some highly selected patients may benefit from low-dose colchicine (traditionally used for gout), which has been shown in some trials to reduce the risk of future heart attacks [11][12]. This is not a routine drug for everyone and requires careful review of your kidney, liver, and drug interaction risks.

Medical Therapy vs. Stents: The ISCHEMIA Trial

One of the most important studies in modern cardiology, the ISCHEMIA trial, compared an “invasive” strategy (stents or bypass surgery plus medications) to a “conservative” strategy (medications and lifestyle changes alone) in over 5,000 patients with stable disease and moderate-to-severe ischemia [13].

The trial’s findings were groundbreaking: for these selected patients with stable disease, an initial strategy of intensive medical therapy was just as safe as stents or surgery at preventing the main composite of death or heart attacks over several years [1][13].

  • The Key Difference: Stents and surgery were better at reducing the frequency of chest pain (angina) for those who had daily or weekly symptoms [14].
  • The Conclusion: If your symptoms are well-controlled with medication, you are not generally at a higher risk of death by choosing to avoid a procedure. Stents are primarily used to improve your quality of life by reducing pain, not necessarily to extend your life in this specific population [1][14]. However, this does not apply to patients with ACS, left-main disease, or severe ventricular dysfunction, where procedures often provide crucial survival benefits.

Lifestyle: The Invisible Prescription

Medication works best when paired with lifestyle changes. These are not “suggestions” but are considered essential parts of GDMT [2]:

  1. Tobacco Cessation: Quitting smoking is arguably the single most impactful thing you can do for your heart health [2].
  2. Cardiac Rehabilitation: This is a supervised program of exercise and education. Research shows it significantly improves outcomes, yet it is often underused [15][16].
  3. Blood Pressure & Diabetes Control: Keeping your blood pressure controlled (often targeted below 140/90 mmHg or 130/80 mmHg depending on your specific risks) and managing blood sugar (such as an HbA1c <7% for some patients) are critical targets to protect your arteries from further damage [17][18]. Discuss your personalized goals with your doctor.

By embracing GDMT, you are taking an active role in protecting your heart against future problems [19].

Common questions in this guide

What does guideline-directed medical therapy mean for coronary stenosis?
Guideline-directed medical therapy combines evidence-based medicines with lifestyle changes to lower heart risks, stabilize plaque, and control symptoms. It may include cholesterol-lowering treatment, antiplatelet medicine, anti-anginal drugs, smoking cessation, cardiac rehabilitation, and control of blood pressure and diabetes.
Can coronary stenosis be treated without a stent?
For selected people with stable coronary disease and controlled symptoms, intensive medical therapy can be as safe as starting with a stent or bypass surgery for preventing death or heart attack over several years. Procedures may still be important when symptoms remain limiting or when someone has an acute coronary syndrome, left-main disease, or severely reduced heart function.
What medicines are commonly used for coronary stenosis?
Treatment may include a statin, with ezetimibe or a PCSK9 inhibitor added when cholesterol remains above the person’s target. Aspirin or clopidogrel may reduce clot risk, while beta-blockers, calcium-channel blockers, nitroglycerin, or ranolazine can help relieve chest pain. The exact combination depends on symptoms, other health conditions, bleeding risk, and prior procedures.
What LDL cholesterol level might be the goal with coronary stenosis?
Many people are treated toward an LDL cholesterol level of 70 mg/dL or lower, while some high-risk recommendations use a target below 55 mg/dL. The appropriate goal depends on your overall cardiovascular risk, and your clinician may add ezetimibe or a PCSK9 inhibitor if a statin alone is not enough.
Which lifestyle changes help manage coronary stenosis?
Quitting tobacco is one of the most important ways to protect the heart. Cardiac rehabilitation provides supervised exercise and education, while controlling blood pressure and diabetes can help prevent further artery damage. Your care team can set targets suited to your health and risk level.
Is it safe to stop aspirin or clopidogrel if I feel well?
Do not stop a prescribed antiplatelet medicine without speaking with your cardiologist, especially after a stent. The duration and choice of treatment depend on your risk of bleeding, heart attack history, and whether you have had a procedure. Stopping too soon after a stent can cause a dangerous clot.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Are my current LDL cholesterol and blood pressure levels at the personalized targets for my level of risk?
  2. 2.Am I a candidate for 'high-intensity' statin therapy, and if my LDL remains above target, should we consider adding ezetimibe or a PCSK9 inhibitor?
  3. 3.Based on the ISCHEMIA trial results, is my angina stable enough to continue with medical therapy alone rather than a stent or bypass?
  4. 4.Given my specific medical history and kidney function, would a trial of low-dose colchicine be safe and appropriate for me?
  5. 5.What is my personal risk of bleeding versus my risk of a heart attack when deciding on the duration of my antiplatelet therapy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Implications of the Landmark ISCHEMIA Trial on the Initial Management of High-Risk Patients with Stable Ischemic Heart Disease.

    Vafaei P, Naderi S, Ambrosy AP, Slade JJ

    Current atherosclerosis reports 2021; (23(11)):70 doi:10.1007/s11883-021-00970-z.

    PMID: 34468881
  2. 2

    2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures.

    Williams MS, Levine GN, Kalra D, et al.

    Journal of the American College of Cardiology 2025; (85(25)):2504-2535 doi:10.1016/j.jacc.2025.02.001.

    PMID: 40310322
  3. 3

    The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better.

    Mhaimeed O, Burney ZA, Schott SL, et al.

    American journal of preventive cardiology 2024; (18()):100649 doi:10.1016/j.ajpc.2024.100649.

    PMID: 38576462
  4. 4

    Invasive versus Conservative Management in Coronary Artery Disease.

    Rezkalla SH, Kloner RA

    Clinical medicine & research 2023; (21(2)):95-104 doi:10.3121/cmr.2023.1806.

    PMID: 37407216
  5. 5

    Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.

    Schwartz GG, Steg PG, Szarek M, et al.

    The New England journal of medicine 2018; (379(22)):2097-2107 doi:10.1056/NEJMoa1801174.

    PMID: 30403574
  6. 6

    Should We Use Aspirin or P2Y12 Inhibitor Monotherapy in Stable Ischemic Heart Disease?

    Chandiramani R, Mehta A, Blumenthal RS, Williams MS

    Current atherosclerosis reports 2024; (26(11)):649-658 doi:10.1007/s11883-024-01234-2.

    PMID: 39243345
  7. 7

    P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events.

    Gragnano F, Cao D, Pirondini L, et al.

    Journal of the American College of Cardiology 2023; (82(2)):89-105 doi:10.1016/j.jacc.2023.04.051.

    PMID: 37407118
  8. 8

    Optimal Medical Therapy for Stable Ischemic Heart Disease: Focus on Anti-anginal Therapy.

    Montelaro BM, Ibrahim R, Thames M, Mehta PK

    The Medical clinics of North America 2024; (108(3)):455-468 doi:10.1016/j.mcna.2023.12.006.

    PMID: 38548457
  9. 9

    Treatment of Angina: Where Are We?

    Balla C, Pavasini R, Ferrari R

    Cardiology 2018; (140(1)):52-67 doi:10.1159/000487936.

    PMID: 29874661
  10. 10

    Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: A review of the evidence.

    Ambrosio G, Tamargo J, Grant PJ

    Diabetes & vascular disease research 2016; (13(2)):98-112 doi:10.1177/1479164115609028.

    PMID: 26873904
  11. 11

    Colchicine in Coronary Artery Disease: Comparative Review of CLEAR SYNERGY, LoDoCo2 and COLCOT.

    Jannink J, van Zelm AM, Chemlal S, et al.

    Current atherosclerosis reports 2026; (28(1)):11 doi:10.1007/s11883-025-01382-z.

    PMID: 41528549
  12. 12

    Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis.

    Samuel M, Berry C, Dubé MP, et al.

    European heart journal 2025; (46(26)):2552-2563 doi:10.1093/eurheartj/ehaf174.

    PMID: 40314333
  13. 13

    Initial Invasive or Conservative Strategy for Stable Coronary Disease.

    Maron DJ, Hochman JS, Reynolds HR, et al.

    The New England journal of medicine 2020; (382(15)):1395-1407 doi:10.1056/NEJMoa1915922.

    PMID: 32227755
  14. 14

    Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease.

    Spertus JA, Jones PG, Maron DJ, et al.

    The New England journal of medicine 2020; (382(15)):1408-1419 doi:10.1056/NEJMoa1916370.

    PMID: 32227753
  15. 15

    Cardiac Rehabilitation for Patients With Stable Ischemic Heart Disease Without Revascularization - Rationale and Design of a Single-Arm Pilot Study.

    Seki T, Murata M, Takabayashi K, et al.

    Circulation reports 2023; (5(3)):90-94 doi:10.1253/circrep.CR-22-0131.

    PMID: 36909138
  16. 16

    EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries.

    Kotseva K, Wood D, De Bacquer D, et al.

    European journal of preventive cardiology 2016; (23(6)):636-48 doi:10.1177/2047487315569401.

    PMID: 25687109
  17. 17

    Attainment of Guideline-Directed Medical Treatment in Stable Ischemic Heart Disease Patients With and Without Chronic Kidney Disease.

    Koutroumpakis E, Gosmanova EO, Stahura H, et al.

    Cardiovascular drugs and therapy 2019; (33(4)):443-451 doi:10.1007/s10557-019-06883-z.

    PMID: 31123935
  18. 18

    Optimal Medical Therapy for Stable Ischemic Heart Disease in 2024: Focus on Blood Pressure and Lipids.

    Abrahams T, Nicholls SJ, Nelson AJ

    The Medical clinics of North America 2024; (108(3)):441-453 doi:10.1016/j.mcna.2023.12.005.

    PMID: 38548456
  19. 19

    Outcomes According to Coronary Revascularization Modality in the ISCHEMIA Trial.

    Redfors B, Stone GW, Alexander JH, et al.

    Journal of the American College of Cardiology 2024; (83(5)):549-558 doi:10.1016/j.jacc.2023.11.002.

    PMID: 37956961

This page is for informational purposes only and does not constitute medical advice. It explains treatment options for coronary stenosis, but your cardiology team should guide medication changes, antiplatelet use, and decisions about stents or surgery.

Get notified when new evidence is published on coronary stenosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.